Jackson Square Capital’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

Jackson Square Capital’s Portfolio PRDS Stock Details PRDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-26,396	Closed	-$47.8K	–	126
2023 Q2	$47.8K	Hold	26,396	–	–	0.02%	112
2023 Q1	$34.8K	Hold	26,396	–	–	0.02%	107
2022 Q4	$44.6K	Hold	26,396	–	–	0.02%	119
2022 Q3	$49K	Buy	+26,396	New	+$78.7K	0.02%	121

Other funds holding PRDS

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Jackson Square Capital's PRDS Position: Q3 2023 in Review

Jackson Square Capital sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q3 2023, closing a stake of 26,396 shares — an estimated $47.8K sold.

Jackson Square Capital first reported a position in PRDS in Q3 2022 and held it in 4 quarters. The position peaked at $49K in Q3 2022. 1 fund tracked by Wall St. Rank holds PRDS as of Q3 2023.

Jackson Square Capital reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Jackson Square Capital sold 26,396 Pardes Biosciences, Inc. Common Stock shares in Q3 2023, an estimated $47.8K.
Jackson Square Capital first reported a position in Pardes Biosciences, Inc. Common Stock in Q3 2022 and held it in 4 quarters.
Jackson Square Capital's Pardes Biosciences, Inc. Common Stock position peaked at $49K in Q3 2022.
1 fund tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q3 2023.

Based on Jackson Square Capital's 13F filing for Q3 2023, filed 25 Oct 2023.